Omnicell (OMCL) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
4 Nov, 2026Executive summary
Q3 2026 revenue was $307.851M, down 1% YoY; non-GAAP EBITDA rose 9% to $44.931M, and non-GAAP diluted EPS rose 14% to $0.58.
Revenue and non-GAAP EBITDA exceeded the high end of prior guidance, supported by favorable margins, mix, cost efficiency and disciplined spending.
Titan XT and OmniSphere drew customer interest as the pipeline advanced; bookings remain sensitive to customer timing and are expected to be back-end weighted in 2026.
Financial highlights
Q3 product revenue was $173.052M, down from $177.498M; service revenue was $134.799M, up from $133.133M.
Q3 GAAP net income was $11.044M versus $5.462M; non-GAAP net income was $27.039M versus $23.526M.
Q3 non-GAAP gross margin was 45.4%, up 120 bps YoY; non-GAAP operating expenses were $108M, down 2%.
9M revenue rose 7% to $929.939M; 9M gross margin was 46% versus 43%, including a $14.0M IEEPA tariff refund recorded primarily as a reduction to product costs.
Outlook and guidance
FY 2026 guidance: revenue $1.225B–$1.231B, product revenue $684M–$687M, service revenue $541M–$544M, product bookings $425M–$560M and year-end ARR $660M–$670M.
FY non-GAAP EBITDA guidance increased to $187M–$193M and non-GAAP EPS to $2.48–$2.56; remaining guidance was reiterated, with revenue, product, service and ARR ranges tightened.
Q4 guidance: revenue $295M–$301M, product revenue $161M–$164M, service revenue $134M–$137M, non-GAAP EBITDA $30M–$36M and non-GAAP EPS $0.41–$0.49.
FY recurring revenue is projected at 52% of total revenue, including SaaS and Expert Services at 22%; bookings outlook is back-end weighted amid deal timing and conversion uncertainty.
Competitive conversions may take 9–12 months, and larger customer rollouts may span multiple quarters.
Latest events from Omnicell
- Advanced Services grew as FY2023 revenue and bookings declined.OMCL
Q4 2023 - Titan XT and OmniSphere drive a flexible, customer-focused refresh cycle with strong financial discipline.OMCL
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue rose 7% to $312M, with higher margins and a $14M–$15M tariff refund.OMCL
Q2 2026 - Growth accelerates with new cloud-based products, AI integration, and a focus on recurring revenue.OMCL
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Titan XT and OmniSphere launch drive a pivotal product cycle and margin-focused strategy.OMCL
Bank of America Global Healthcare Conference 2026 - Q1 2026 saw 15% revenue growth, margin gains, and raised profit guidance.OMCL
Q1 2026 - 2026 meeting seeks approval for director elections, pay, equity plan, officer exculpation, and auditor.OMCL
Proxy filing - Proxy seeks approval on director elections, compensation, equity plan, officer exculpation, and auditor.OMCL
Proxy filing - Q3 revenue fell 5% to $282M, net income rose, and 2024 guidance for EBITDA and EPS increased.OMCL
Q3 2024